Tags

Type your tag names separated by a space and hit enter

Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis.
Hamostaseologie. 2020 Aug; 40(3):264-269.H

Abstract

The novel coronavirus, SARS-CoV-2, is causing a global pandemic of life-threatening multiorgan disease, called COVID-19. Accumulating evidence indicates that patients with COVID-19 are at significant risk of thromboembolic complications, mainly affecting the venous, but also the arterial vascular system. While the risk of venous thromboembolism (VTE) appears to be higher in patients requiring intensive care unit support compared to those admitted to general wards, recent autopsy findings and data on the timing of VTE diagnosis relative to hospitalization clearly suggest that thromboembolic events also contribute to morbidity and mortality in the ambulatory setting. In addition to a severe hypercoagulable state caused by systemic inflammation and viral endotheliitis, some patients with advanced COVID-19 may develop a coagulopathy, which meets established laboratory criteria for disseminated intravascular coagulation, but is not typically associated with relevant bleeding. Similar to other medical societies, the Society of Thrombosis and Haemostasis Research has issued empirical recommendations on initiation, dosing, and duration of pharmacological VTE prophylaxis in COVID-19 patients.

Authors+Show Affiliations

Zentrum für Onkologie, II. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.Klinik für Intensivmedizin, Zentrum für Anästhesiologie und Intensivmedizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.Zentrum für Gefäβmedizin, Klinik für Innere Medizin - Angiologie und Hämostaseologie, Vivantes Klinikum im Friedrichshain, Berlin, Germany.Institut für Experimentelle Hämatologie und Transfusionsmedizin, Universitätsklinik Bonn, Bonn, Germany.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32498097

Citation

Langer, Florian, et al. "Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis." Hamostaseologie, vol. 40, no. 3, 2020, pp. 264-269.
Langer F, Kluge S, Klamroth R, et al. Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis. Hamostaseologie. 2020;40(3):264-269.
Langer, F., Kluge, S., Klamroth, R., & Oldenburg, J. (2020). Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis. Hamostaseologie, 40(3), 264-269. https://doi.org/10.1055/a-1178-3551
Langer F, et al. Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis. Hamostaseologie. 2020;40(3):264-269. PubMed PMID: 32498097.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis. AU - Langer,Florian, AU - Kluge,Stefan, AU - Klamroth,Robert, AU - Oldenburg,Johannes, Y1 - 2020/06/04/ PY - 2020/6/5/pubmed PY - 2020/8/7/medline PY - 2020/6/5/entrez SP - 264 EP - 269 JF - Hamostaseologie JO - Hamostaseologie VL - 40 IS - 3 N2 - The novel coronavirus, SARS-CoV-2, is causing a global pandemic of life-threatening multiorgan disease, called COVID-19. Accumulating evidence indicates that patients with COVID-19 are at significant risk of thromboembolic complications, mainly affecting the venous, but also the arterial vascular system. While the risk of venous thromboembolism (VTE) appears to be higher in patients requiring intensive care unit support compared to those admitted to general wards, recent autopsy findings and data on the timing of VTE diagnosis relative to hospitalization clearly suggest that thromboembolic events also contribute to morbidity and mortality in the ambulatory setting. In addition to a severe hypercoagulable state caused by systemic inflammation and viral endotheliitis, some patients with advanced COVID-19 may develop a coagulopathy, which meets established laboratory criteria for disseminated intravascular coagulation, but is not typically associated with relevant bleeding. Similar to other medical societies, the Society of Thrombosis and Haemostasis Research has issued empirical recommendations on initiation, dosing, and duration of pharmacological VTE prophylaxis in COVID-19 patients. SN - 2567-5761 UR - https://www.unboundmedicine.com/medline/citation/32498097/Coagulopathy_in_COVID_19_and_Its_Implication_for_Safe_and_Efficacious_Thromboprophylaxis_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/a-1178-3551 DB - PRIME DP - Unbound Medicine ER -